Cutanos

Executive Summary

Cutanos is a Vienna-based private biotechnology company founded in 2020, focusing on immune modulation via dendritic cells (DCs). The company aims to harness DCs’ dual role in orchestrating immune responses against pathogens and maintaining tolerance to self-antigens. By developing novel delivery technologies, Cutanos seeks to precisely tune this balance for therapeutic applications in immunotherapy, autoimmune diseases, and vaccination. Currently in early preclinical stages, the company has not disclosed specific pipeline assets or funding rounds. Its technology could potentially address key limitations in existing immunotherapies by enabling targeted activation or suppression of immune responses. As a young spinout from Austrian academic institutions, Cutanos represents an early-stage investment opportunity with high scientific risk but potential for breakthrough in immune-modulating drug delivery.

Upcoming Catalysts (preview)

• H2 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal60% success
• 2026–2027Closing of seed or Series A financing round50% success
• 2027Announcement of a research collaboration or licensing agreement with a larger pharma or biotech30% success